Is this Gilead's Biggest Risk?

Gilead looks gilded right now, but could the company's huge success threaten its future?

Jun 13, 2014 at 5:00PM

I'll get right to the punch line.

Gilead Sciences (NASDAQ:GILD) revolutionary approach to hepatitis C brought in an eye-popping $2.3 billion in its first quarter. If all goes as planned, sales could reach $9 billion by 2017, on target to make Sovaldi one of the best-selling drugs of all time.

So let's dream a little bit. The knock on Gilead has always been its over-reliance on its HIV pipeline. But if all the hepatitis C infections were eventually treated at Sovaldi's list price, Gilead would make an amount that makes the $2.3 billion last quarter look tiny. 

Time to break out the pretzels and beer? Not quite yet.

Here's the downside. Sovaldi's incredible success could be planting the seeds of Gilead's downfall. The drug's pricing--$84,000 over the 12-week course of treatment--has had such a massive and disruptive impact on the insurance and medical industries, the company risks becoming a victim of its own success.

In fact, Sovaldi poses a huge riddle for Gilead. How can a $1,000 pill designed overwhelmingly for those who are low-income, or live in low- income countries, become accessible to the patients who need it most?

In the United States, more than half of the three million infected with the virus are on some form of guaranteed federal medical assistance, be they prisoners or Medicaid-recipients. That's why, ever since Sovaldi was approved at the end of December, lawmakers have been worried it could be the final straw laid on the taxpayer's back.

Anger is mounting internationally, and Gilead is taking note. The danger Sovaldi's success poses was by far the most significant risk in the company's 10-Q filing. Gilead must maintain or continue increasing sales of Sovaldi, the filing stated, otherwise "our results of operations may be adversely affected."

Just a few days ago, John Milligan, Gilead's COO, elaborated further. At the William Blair stockholders' meeting in Chicago, Milligan frankly admitted that the 30,000 patients treated with Sovaldi in Q1 were more than the company had originally estimated. He also said that Gilead was going through "pricing and reimbursement discussions across the European Union."

Here's what's likely keeping Milligan up at night. Since Sovaldi is essentially a cure, Gilead has to keep finding new hepatitis C patients to treat if it wants to keep posting incredible sales. And those new patients must be able to pay for the drug, or have their insurers pay for it. And with the continued payer pushback in the U.S., that may become a bit of a problem.

This problem will be ongoing every quarter, confounded by different factors (including increasing competition over the long term). In the near term, Gilead faces a risk doctors may choose to wait to treat hepatitis C patients until later in 2014, when the fixed-dose combination Sovaldi + Ledipasvir becomes available.

At the very least, the need to find all those new patients each quarter will make Gilead's quarterly numbers lumpy. And the ride for Gilead investors? A roller coaster.

The long-term picture
So why am I long Gilead? No one has a crystal ball. But despite significant payer pushback, drug pricing in the United States has yet to become vulnerable, and I believe that story is still intact.

Gilead's competition apparently agrees with me. Merck & Co.(NYSE:MRK) just paid a staggering $3.85 billion for Idenix Pharmaceuticals (NASDAQ:IDIX) despite the fact its hepatitis C drugs are still in early stages of development. The deal is a gambit to offer a competitive hep-C therapy. But with that kind of a price tag for a small, clinical-stage biotech, Merck is more or less admitting they must immediately shore up their arsenal of potential drugs for hep C, or concede the market to Gilead.

Idenix's most promising drug is Samatasvir, a drug in phase 2 that could easily fall into the same pit that made Bristol-Myers scrap Inhibitex's therapy after they paid $2.5 billion for it. At best, Samatasvir has a long pathway to commercialization in front of it. Gilead, for instance, acquired Sovaldi when it bought Pharmasset for $11 billion in 2011, but was not able to begin selling Sovaldi until Q4 2013.

The American way: tax and prescribe
Gilead is sensitive to anger about Sovaldi's pricing--outside the United States. The drug sports the usual tiered pricing scheme. U.S. patients and their insurers pay the most. In Europe, Sovaldi is significantly reduced. Right now, Gilead is talking to generic drug-makers in India about setting Sovaldi's price at $2,000 per treatment course, or 2% of the U.S. price for 60 low-income companies.

Gilead has other catalysts coming this year. But bottom line, nothing in Gilead's pipeline will rescue the stock if the company is forced to lower prices in the U.S. and shrink its Sovaldi windfall.

Will that happen? I seriously doubt it. After all, the costs of paying for liver failure are much higher than curing hep C.

Hepatitis c is one of the most common and dangerous viral epidemics afflicting mankind, and there's no real competition for Sovaldi yet (although AbbVie's drug may come on line relatively soon). That puts Gilead were stockholders need it to be -- squarely in the driver's seat. Watch Sovaldi sales moving forward, but I'm still excited about the stock's potential.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Cheryl Swanson owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers